Method for performing specific partition on ACE2 and application thereof

Through MutaBind2 protein mutation calculation and SPR verification, the binding interface of ACE2 protein and SARS-CoV-2RBD in a specific partition solves the unsolved problem of the binding mechanism of ACE2 molecules to the new coronavirus, and provides theoretical support for the potential host range of the new coronavirus and drug development. .

CN118942535APending Publication Date: 2024-11-12WUYI UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310528941.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-10
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The existing technology has not yet fully solved the contribution of key subdomains of ACE2 molecule to SARS-CoV-2 to cross-species infection of the new coronavirus, affecting the establishment of animal models and the development of targeted drugs.

Method used

Protein mutation calculation and prediction were carried out through MutaBind2, and the binding interface of specific partition ACE2 proteins and SARS-CoV-2RBD, including amino acid residue mutations and SPR technology verification, divided subregional structures CR1, CR2, and CR3, and explored their impact on binding affinity .

Benefits of technology

The key sites of the contact interface between ACE2 and the new coronavirus were analyzed, and the impact of ACE2 substructure regions on binding affinity of different species was explored, providing theoretical support for predicting the potential host range of the new coronavirus and the development of antibodies and vaccines.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0004223899550000011
    Figure HDA0004223899550000011
  • Figure HDA0004223899550000012
    Figure HDA0004223899550000012
  • Figure HDA0004223899550000021
    Figure HDA0004223899550000021
Patent Text Reader

Abstract

The invention discloses a method for carrying out specific partition on ACE2 and application of the method. The method comprises the following steps: carrying out protein mutation calculation and prediction on a compound crystal structure of ACE2 protein and SARS-CoV-2RBD by utilizing mutabind2, and carrying out specific partition on the ACE2 according to an interface contact point of the ACE2 protein and a new coronavirus. The method disclosed by the invention can be used for exploring key amino acid residues of interaction between the SARS-CoV-2RBD and the ACE2 and the influence of different substructure regions of the ACE2 of a specific species on the binding affinity of the SARS-CoV-2RBD and the ACE2 in the process that different species are infected by the new coronavirus. And a theoretical support is provided for predicting a potential host range of the new coronavirus and researching and developing antibodies and vaccines.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine, and specifically relates to a method for performing specific partitioning of ACE2 and an application thereof. Background Art

[0002] The 2019 novel coronavirus disease (COVID-19) has become an international public health emergency, posing the most serious threat to global human health. Increasing evidence shows that the novel coronavirus can infect not only humans but also other species, leading to cross-species infection. In order to more quickly, systematically and accurately discover species with highly cross-species infection characteristics, it is necessary to study the key sites where ACE2 binds to SARS-CoV-2.

[0003] However, the contribution of the key subdomain of the ACE2 molecule of the relevant species as a receptor to the binding of SARS-CoV-2 to affinity and even its importance in whether the relevant species is a potential host for the transmission of the new coronavirus has not yet been fully understood, and more in-depth research is needed, which is of great significance for the establishment of animal models and the development of targeted drugs. Summary of the invention

[0004] The present invention aims to solve at least one of the technical problems existing in the above-mentioned prior art. To this end, the present invention proposes a method for performing specific partitioning on ACE2.

[0005] The invention also proposes the application of the method.

[0006] According to one aspect of the present invention, a method for specifically partitioning ACE2 is proposed, and the method comprises the following steps: using mutabind2 to perform protein mutation computational prediction on the crystal structure of the complex of ACE2 protein and SARS-CoV-2RBD, and specifically partitioning ACE2 according to the interface contact points between ACE2 protein and the new coronavirus.

[0007] In some embodiments of the present invention, the method further comprises the step of mutating the amino acid residues at all key sites of the SARS-CoV-2S protein and / or the human ACE2 protein to alanine.

[0008] In some embodiments of the present invention, ACE2 proteins include but are not limited to human, cat, white-tailed deer, mouse and mutant ACE2 proteins.

[0009] In some embodiments of the present invention, the mutated ACE2 protein includes a hACE2 mutant strain in which the key domain is replaced with amino acid residues at the same position of the experimental species using human ACE2 (ACE2 is a monomer ACE2 (1-615)) as a skeleton.

[0010] In some embodiments of the invention, the PDB ID of the complex crystal structure of ACE2 and SARS-CoV-2 RBD includes 6M0J.

[0011] In some embodiments of the present invention, MutaBind2 is used to obtain the three-dimensional structure file (PD B6M0J) of the co-crystal of SARS-CoV-2S protein and human ACE2 protein from the protein structure database (https: / / ww w.rcsb.org / ), and then perform mutation calculations on some key amino acid residues in the protein complex on the MutaBind2 (https: / / lilab.jysw.suda.edu.cn / research / mutabind2 / method) website.

[0012] For each protein / mutation, Mutabind2 provides the following results:

[0013] ΔΔGbind (kcal / mol) is the predicted change in binding affinity induced by the mutation. Positive and negative signals correspond to destabilizing and stabilizing mutations, which are expected to decrease and increase binding affinity respectively. The MutaBind server classifies mutations as deleterious if ΔΔG≥1.5 kcal / mol, and considers mutations to promote binding if ΔΔG≤-1.5 kcal / mol.

[0014] In some embodiments of the present invention, the specific partition is obtained by dividing the binding interface between ACE2 and SARS-CoV-2RBD into subregional structures according to their spatial structure and interaction force.

[0015] In some embodiments of the present invention, the sub-region structure includes CR1, CR2 and CR3.

[0016] In some embodiments of the present invention, the ACE2 amino acid sites in the CR1 include Q24, T27, F28, K31, L79, M82 and Y83.

[0017] In some embodiments of the present invention, the ACE2 amino acid sites in the CR2 include T27, D30, K31, H34 and E35.

[0018] In some embodiments of the present invention, the ACE2 amino acid sites in the CR3 include E37, D38, Y41, Q42, N330, K353, G354, D355, R357 and R393.

[0019] In some embodiments of the present invention, the method further comprises a step of verification using SPR technology.

[0020] In some embodiments of the present invention, the step of verifying by SPR technology includes: using SPR technology to determine the affinity and kinetic parameters of ACE2 proteins of different species and SARS-CoV-2RBD.

[0021] In some embodiments of the present invention, the ACE2 proteins of different species and SARS-CoV-2 RBD are proteins obtained by induced expression and purification through cell engineering methods.

[0022] In some embodiments of the present invention, the purification is performed using an AKTA purifier.

[0023] In some embodiments of the present invention, the tag for purifying ACE2 proteins of different species is a His tag.

[0024] In some embodiments of the present invention, the tag for purifying SARS-CoV-2 RBD is an Fc tag.

[0025] In some embodiments of the present invention, the step of purifying ACE2 protein by AKTA purifier includes: subjecting the ACE2 expression protein to be purified to affinity chromatography on a nickel column, and then purifying it using molecular sieves to obtain the purified expression protein.

[0026] In some embodiments of the present invention, the solution used for the affinity chromatography purification includes a nickel column equilibrium solution and a nickel column eluent.

[0027] In some embodiments of the present invention, the nickel column equilibrium solution includes 150-250 mM NaCl, 15-25 mM Tris and 15-25 mM Imidazole, and the pH is 7.0-8.0.

[0028] In some embodiments of the present invention, the nickel column equilibration solution includes 200 mM NaCl, 20 mM Tris and 20 mM Midazole, and the pH value is 7.5.

[0029] In some embodiments of the present invention, the nickel column eluent comprises 450-550 mM Imidazole, 15-25 mM Tris and 150-250 mM NaCl, with a pH of 7.5.

[0030] In some embodiments of the present invention, the nickel column eluent comprises 500 mM Imidazole, 20 mM Tris and 200 mM NaCl, with a pH of 7.5.

[0031] In some embodiments of the present invention, the step of purifying SARS-CoV-2RBD protein by AKTA purifier includes: affinity purification by Protein A column using AKTA purifier and then further purification by molecular sieve.

[0032] In some embodiments of the present invention, the affinity chromatography purification solution is citric acid at pH 3.5 and citric acid at pH 3.0.

[0033] In some embodiments of the present invention, molecular sieve purification uses molecular sieve solution and 0.1M NaOH solution to obtain high-purity protein through a double purification operation step.

[0034] In some embodiments of the present invention, the molecular sieve solution includes 10 mM PB and 140 mM NaCl, and the pH is 7.4.

[0035] In some embodiments of the present invention, the concentration of the purified protein further comprises a step of measuring the concentration using the BCA method.

[0036] In some embodiments of the present invention, the SPR assay is performed using a Protein A chip.

[0037] In some embodiments of the present invention, the Protein A chip captures SARS-CoV-2 RBD carrying an Fc tag at a concentration of 1 g / ml, and different ACE2s flow through the chip surface in a concentration range of 2000 nM to 31.25 nM, with two-fold gradient dilutions, and the binding kinetics are analyzed using Biacore Insight evaluation software and a 1:1 binding model.

[0038] In some embodiments of the present invention, the solution used in SPR includes 10 mM HEPES, 0.005% Tween-20, 3 mM EDTA, 150 mM NaCl, ligand SARS-CoV-2 RBD and analyte ACE2.

[0039] In some embodiments of the invention, the concentration of the ligand SARS-CoV-2 RBD is 1 g / ml and the concentration of the analyte ACE2 is 0-2000 nM.

[0040] In some embodiments of the invention, the concentration of the analyte ACE2 is 2000 nM, 1000 nM, 500 nM, 250 nM, 125 nM, 62.5 nM, 31.25 nM and 0 nM.

[0041] According to the second aspect of the present invention, an application of the above method is proposed, and the application is the application in the preparation of drugs for preventing and treating new coronavirus.

[0042] In some embodiments of the present invention, the method is used in the preparation of products for analyzing key sites of the contact interface between ACE2 and the new coronavirus.

[0043] In some embodiments of the present invention, the method is used in the preparation of a product for analyzing the binding ability of ACE2 and the SARS-CoV-2 spike protein.

[0044] According to some embodiments of the present invention, at least the following beneficial effects are achieved: the scheme of the present invention combines protein mutation calculation prediction to perform substructure partitioning on ACE2, partitions ACE2 and SARS-CoV-2RBD through SPR experiments, studies the effects of substructure mutations on binding affinity, and analyzes the key sites of the contact interface between ACE2 and the new coronavirus. The above method can be used to explore the key amino acid residues of the interaction between SARS-CoV-2RBD and ACE2, as well as the effects of different substructure regions of ACE2 of specific species on the binding affinity of the two during the infection of different species by the new coronavirus, that is, the cross-structure ACE2 tropism of the virus, providing theoretical support for predicting the potential host range of the new coronavirus, and the development of antibodies and vaccines. BRIEF DESCRIPTION OF THE DRAWINGS

[0045] The present invention will be further described below with reference to the accompanying drawings and embodiments, wherein:

[0046] Figure 1 This is a diagram showing the calculation results of the key site mutation of the ACE2 protein in Example 1 of the present invention;

[0047] Figure 2 This is a diagram showing the calculation results of the key site mutations of the human SARS-CoV-2 RBD protein in Example 1 of the present invention;

[0048] Figure 3 This is a diagram showing the calculation results of the mutation of the amino acid residues at the same position of mouse in human ACE2 in Example 1 of the present invention;

[0049] Figure 4 This is a diagram showing the calculation results of the mutation of the amino acid residues at the same position of pig in human ACE2 in Example 1 of the present invention;

[0050] Figure 5 This is a diagram of the binding interface between human ACE2 and SARS-CoV-2 RBD protein in Example 1 of the present invention. Pink is ACE2, light blue is SARS-CoV-2 RBD, and yellow is the interaction force between the two. The contact distance is ≤ PDB ID: 6M0J;

[0051] Figure 6 This is a diagram showing the calculation results of sub-region mutations of different species in Example 1 of the present invention;

[0052] Figure 7 This is a diagram of the plasmid sequencing results in Example 1 of the present invention;

[0053] Figure 8 This is the SPR result diagram in Example 1 of the present invention;

[0054] Fig. 9 This is a diagram of the key action site binding of ACE2 and SARS-CoV-2 RBD in Example 1 of the present invention, wherein cyan is ACE2, pink is SARS-CoV-2 RBD, and the contact distance is ≤

[0055] Fig.10 is a sequence comparison diagram in Example 1 of the present invention;

[0056] Fig.11 This is the biological system development tree diagram in Example 1 of the present invention. DETAILED DESCRIPTION

[0057] The following will be combined with the embodiments to clearly and completely describe the concept of the present invention and the technical effects produced, so as to fully understand the purpose, characteristics and effects of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, other embodiments obtained by those skilled in the art without creative work are all within the scope of protection of the present invention.

[0058] Example 1

[0059] This embodiment provides a method for performing specific partitioning on ACE2, and the specific process is as follows:

[0060] The crystal structure file (6M0J) of hACE2 / SARS-CoV-2RBD obtained from the PDB website was opened in the PyMoL software to determine the key sites for ACE2 to bind to SARS-CoV-2RBD. MutaBin d2 (https: / / lilab.jysw.suda.edu.cn / research / mutabind2 / method) was used to calculate the mutation of the sites, and the amino acid residues at all key sites of ACE2 and SARS-CoV-2RBD were mutated to A (alanine, because its structure is the simplest). For protein mutations, Mutabind2 provides the following results:

[0061] ΔΔGbind (kcal / mol) is the predicted change in binding affinity induced by the mutation. Positive and negative signals correspond to destabilizing and stabilizing mutations, which are expected to decrease and increase binding affinity respectively. If ΔΔG≥1.5kcal / mol, the MutaBind server classifies the mutation as deleterious, and if ΔΔG≤-1.5kcal / mol, the mutation is considered to promote binding (the calculation results are shown by DDG).

[0062] pass Figure 1-2 The results show that some DDGs are negative, which means that mutations may promote the binding of the two. Then, the key sites of human ACE2 were mutated to the amino acid residues corresponding to the same positions of mice and pigs for mutation calculation (because mice do not bind to SARS-CoV-2 RBD and the affinity of pig ACE2 is similar to that of human ACE2). The results are as follows Figure 3-4 shown.

[0063] According to the spatial structure of the contact site of the binding interface between ACE2 and SARS-CoV-2 RBD and various forces (such as hydrogen bonds and salt bonds), three different sub-region structures are divided, namely CR1, CR2, and CR3 regions. The structure of the binding interface between human ACE2 and SARS-CoV-2 RBD protein is shown in the figure. Figure 3 The specific amino acid sites contained in each substructure region are shown in Table 1.

[0064] Table 1

[0065] Area ACE2 region CR1 Q24, T27, F28, K31, L79, M82T, Y83 CR2 T27, D30, K31, H34, E35 CR3 E37, D38, Y41, Q42, N330, K353, G354, D355, R357, R393

[0066] The amino acid residues of the key structure of the human ACE2 contact interface were further mutated into amino acid residues at the same position in different species through sequence comparison, and the mutation calculation was performed using the MutaBind2 website, such as Figure 6 As shown in the figure, it can be seen that through the above calculations, mutations in the CR1 region will reduce the binding between ACE2 and SARS-CoV-2RBD, while the CR2 region of most species and the CR3 region of a few species can enhance the binding between the two. Therefore, SPR experiments are planned to be carried out in the future to verify it.

[0067] Verifying the effect of the above method on studying the binding of ACE2 to the novel coronavirus spike protein specifically includes the following steps:

[0068] 1. Construction of plasmid

[0069] In this embodiment, 7 plasmids were designed, and the genes of His-tagged protein ACE2 and Fc-tagged protein SARS-CoV-2RBD were constructed in the pcDNA3.1 vector by seamless cloning, and pcDNA3.1 vectors containing ACE2, pcDNA3.1 vectors containing CR1-Ferret, pcDNA3.1 vectors containing CR2-Ferret, pcDNA3.1 vectors containing CR3-Ferret, pcDNA3.1 vectors containing CR1-Cat, pcDNA3.1 vectors containing CR3-Cat, and pcDNA3.1 vectors containing SARS-CoV-2 RBD were constructed respectively.

[0070] For the preparation of pcDNA3.1 vector containing ACE2, the sequence number of the Uniprot protein sequence library of human ACE2 is Q9BYF1, the specific amino acid sequence is shown in SEQ ID NO.1, and its corresponding gene sequence is shown in SEQ ID NO.2. The ACE2 peptidase domain (PD) (residues 1-615) carries a C-terminal 6×His tag for protein purification.

[0071] The mutant strain CR1-Ferret is a mutant containing Q24L, L79H, and M82T produced by site-directed mutagenesis of ACE2; CR2-Ferret is a mutant containing D30E and H34Y produced by site-directed mutagenesis of ACE2; CR3-Ferret is a mutant containing D38E and G354R produced by site-directed mutagenesis of ACE2; CR1-Cat is a mutant containing Q24L and M82T produced by site-directed mutagenesis of ACE2; CR3-Cat is a mutant containing D38E produced by site-directed mutagenesis of ACE2.

[0072] The preparation of the pcDNA3.1 vector containing CR1-Ferret is to connect the mutant strain CR1-Ferret with the pcDNA3.1 vector through seamless cloning; the preparation of the pcDNA3.1 vector containing CR2-Ferret is to connect the mutant strain CR2-Ferret with the pcDNA3.1 vector through seamless cloning; the preparation of the pcDNA3.1 vector containing CR3-Ferret is to connect the mutant strain CR3-Ferret with the pcDNA3.1 vector through seamless cloning; the preparation of the pcDNA3.1 vector containing CR1-Cat is to connect the mutant strain CR1-Cat with the pcDNA3.1 vector through seamless cloning; the preparation of the pcDNA3.1 vector containing CR3-Cat is to connect the mutant strain CR3-Cat with the pcDNA3.1 vector through seamless cloning.

[0073] The SARS-CoV-2 RBD in the pcDNA3.1 vector containing the RBD of SARS-CoV-2 is designed to be fused in series with the N-terminal IL2 signal peptide to ensure protein secretion, and the Fc tag promotes protein purification. The sequence number of the Uniprot protein sequence library of SARS-CoV-2 RBD is P0DTC2, the specific amino acid sequence is shown in SEQ ID NO.3, and the corresponding gene sequence is shown in SEQ ID NO.4.

[0074] The plasmid verified by sequencing was subjected to endotoxin-free plasmid extraction to obtain a plasmid that can be transfected into cells. The sequencing results are as follows Figure 7 shown.

[0075] 2. Protein expression and purification

[0076] For protein purification, ACE2 protein and SARS-CoV-2-RBD protein were first purified by affinity chromatography and then further purified by gel filtration chromatography. The final protein samples were determined by polyacrylamide gel electrophoresis and the protein concentration was quantified using the BCA method.

[0077] 3. SPR experiment

[0078] The purified ACE2 protein and SARS-CoV-2-RBD protein were taken for SPR experiment. The protein molecular weight was measured from the website: http: / / www.detaibio.com / tools / index.php?r=seq-pro-calculator%2Findex, and the theoretical fixed amount of SPR capture ligand was calculated. SPR measured the affinity and kinetic parameters of SARS-CoV-2-RBD and ACE2 protein by capture method using ProteinA chip (chip purchased from Cytiva). Buffer (10mM HEPES, 0.005% Tween-20, 3mM EDTA, 150mM NaCl, pH 7.4) was used as instrument running buffer and protein dilution solution. The binding kinetics were analyzed using Biacore Insight evaluation software 1:1 Langmuir binding model. The concentrations of ACE2 analyte were 2000nM, 1000nM, 500nM, 250nM, 125nM, 62.5nM, 31.25nM and 0nM. The concentration of SARS-CoV-2-RBD was 1g / ml. The SPR results are as follows Figure 8 shown.

[0079] pass Figure 8 The SPR results show that the K of CR1-Ferret (Q24L L79H M82T) and CR1-Cat (Q24LM82T) is similar to that of SARS-CoV-2-RBD.D The K value of human and SARS-CoV-2-RBD D The higher the value (3.85E-07), the lower the affinity, which is consistent with the predicted result that the mutation reduces the affinity of the two. The result of CR2-Ferret (D30E H34Y) is significantly different from that of CR3-Ferret (D38E G354R). The calculated and predicted result of CR3-Ferret (D38EG354R) is to reduce the affinity with SARS-CoV-2-RBD, and the SPR result shows no binding activity, while the K of CR2-Ferret (D30EH34Y) and SARS-CoV-2-RBD is 1. D The value (4.58E-07) is close to the K of humans and SARS-CoV-2-RBD D The value (3.85E-07) and according to the reported study on ferret infection with SARS-CoV-2, it is speculated that the mutations of D30E and H34Y (CR2-Ferret) promote the binding of SARS-CoV-2-RBD, which is consistent with the prediction; the K value of CR3-Cat (D38E) and SARS-CoV-2-RBD D The K value (3.46E-07) is higher than that of human and SARS-CoV-2-RBD D The smaller the value (3.85E-07), the higher the affinity, which is consistent with the result of mutation calculation prediction. Subsequently, PyMOL software was used to compare the structure of ACE2 and SARS-CoV-2-RBD of different species, namely cats, dogs, and horses, at the 38th amino acid (because the sequence similarity between cats and dogs reached 94.16%, and in the biological phylogenetic tree (such as Fig.11 As shown in Figure 2, horses, humans, cats, and dogs do not belong to the same category, and the crystal structures of ACE2 and SARS-CoV-2-RBD of horses, cats, and dogs have been resolved. Fig. 9 As shown in the figure, it can be seen from the structural diagram that the 38th amino acid E38 of ACE2 of the other three species (cat, dog, and horse) has a stronger interaction with SARS-CoV-2-RBD, which indirectly confirms that CR3-Cat (D38E) has a higher affinity with SARS-CoV-2-RBD. Finally, the sequences of ACE2 of humans, cats, dogs, and horses were compared. Fig.10 It can be seen that the key amino acid residue sites in the binding interface between ACE2 and SARS-CoV-2-RBD are conservative except for the 24th, 30th, 34th, 38th, 41st, and 82nd amino acid sites. The above steps verify that the algorithm can provide assistance for studying the key sites of the contact interface between ACE2 and the new coronavirus.

[0080] Exploring the key amino acid residues for the interaction between SARS-CoV-2RBD and ACE2 and the effects of different substructure regions of ACE2 of specific species on the binding affinity of the two during the infection of different species by the new coronavirus, i.e., the cross-structural ACE2 tropism of the virus, can provide theoretical support for predicting the potential host range of the new coronavirus, and the development of antibodies and vaccines. A study found that the latest variant of the new coronavirus, Omicron, could infect mice after mutation. This study indirectly verified the findings of this experiment, and mutations in some key sites of ACE2 can promote binding with SARS-CoV-2RBD.

[0081] The embodiments of the present invention are described in detail above in conjunction with the accompanying drawings, but the present invention is not limited to the above embodiments. Various changes can be made within the knowledge of ordinary technicians in the relevant technical field without departing from the purpose of the present invention. In addition, the embodiments of the present invention and the features in the embodiments can be combined with each other without conflict.

Claims

1. A method for specific partitioning of ACE2, characterized in that: The method comprises the following steps: using mutabind2 to perform protein mutation calculation prediction on the crystal structure of the complex of ACE2 protein and SARS-CoV-2 RBD, and performing specific partitioning of ACE2 according to the interface contact points between ACE2 protein and the new coronavirus.

2. The method according to claim 1, characterized in that The method also includes the step of mutating the amino acid residues at all key sites of the SARS-CoV-2S protein and / or the human ACE2 protein to alanine.

3. The method according to claim 1, characterized in that The specific partition is obtained by dividing the binding interface between ACE2 and SARS-CoV-2RBD into sub-regional structures according to their spatial structure and interaction force.

4. The method according to claim 3, characterized in that The sub-region structure includes CR1, CR2 and CR3.

5. The method according to claim 4, characterized in that The ACE2 amino acid sites in the CR1 include Q24, T27, F28, K31, L79, M82 and Y83.

6. The method according to claim 4, characterized in that The ACE2 amino acid sites in the CR2 include T27, D30, K31, H34 and E35.

7. The method according to claim 4, characterized in that The ACE2 amino acid sites in the CR3 include E37, D38, Y41, Q42, N330, K353, G354, D355, R357 and R393.

8. The method according to claim 1, characterized in that The ACE2 protein includes but is not limited to human, cat, white-tailed deer, mouse and mutant ACE2 proteins; preferably, the mutant ACE2 protein includes hACE2 protein with human ACE2 as the skeleton replacing the key domain with amino acid residues at the same position in different species.

9. Use of the method according to any one of claims 1 to 8 in the preparation of a drug for preventing and treating the new coronavirus.

10. Use of the method described in any one of claims 1 to 8 in the preparation of a product for analyzing the binding ability of ACE2 and the spike protein of the new coronavirus or analyzing key sites of the contact interface between ACE2 and the new coronavirus.